Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 55111-533

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 55111-533). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Ltd, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

Packaging label for Divalproex Sodium Extended-release Tablets, USP 250 mg by Dr. Reddy's Laboratories Ltd. The label indicates the tablets are film-coated, extended-release, for oral use, with a unit dose package of 100 tablets (10 x 10). Storage instructions and dispensing information are also included, along with the NDC 55111-533-30.*

FDA Label Image

Container (Container)

Label for Divalproex Sodium Extended-release Tablets, USP 250 mg by Dr. Reddy's Laboratories Ltd. The oral film-coated tablets come in a 100-count package with once-daily dosing. The label includes instructions for pharmacists to dispense an accompanying medication guide and storage details. The NDC number 55111-533-01 is visible.*

FDA Label Image

Figure1 (Figure1)

A cumulative distribution plot comparing percent reduction in CPS rate for patients treated with Divalproex Sodium Delayed-Release Tablets versus placebo. The x-axis shows percent of patients, and the y-axis shows percent reduction in CPS rate, with improvement upwards and worsening downwards. Two curves represent the treatment and placebo groups.*

FDA Label Image

Figure2 (Figure2)

A cumulative distribution plot showing percentage reduction in CPS rate (%) on the y-axis and percentage of patients on the x-axis for Divalproex Sodium extended-release tablets. Two lines depict treatment response: high dose (solid line) and low dose (dashed line) delayed-release tablets. The graph indicates patient improvement or worsening based on change in CPS rate.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing two groups: Placebo (white bar) and Divalproex Sodium Extended-Release Tablets (black bar). The y-axis shows numerical values, with the placebo group at 0.6 and the Divalproex group at approximately 1.2, indicating a difference between the groups.*

FDA Label Image

Structure (Structure)

Chemical structure of Divalproex Sodium, showing the molecular arrangement with sodium ion and associated organic groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.